Skip to main content

Table 4 Univariate and multivariate analyses of prognostic factors for overall survival in patients with MSKCC-CRS 3–5

From: Is there a survival benefit from adjuvant chemotherapy for patients with liver oligometastases from colorectal cancer after curative resection?

Variable Univariate Multivariate
HR (95% CI) P value HR (95% CI) P value
Age (≤ 60 years vs. > 60 years) 0.945 (0.457–1.955) 0.880   
Sex (male vs. female) 1.014 (0.492–2.090) 0.970   
Primary tumor location (rectum vs. colon) 1.562 (0.754–3.236) 0.230   
Primary tumor differentiation (poor vs. well to moderate) 1.601 (0.732–3.502) 0.160   
T stage (4 vs. 1–3) 1.957 (0.964–3.973) 0.063 2.247 (1.093–4.622) 0.028
N stage (positive vs. negative) 1.139 (0.345–3.760) 0.831   
Timing of metastasis (synchronous vs. metachronous) 1.190 (0.456–3.106) 0.722   
Number of metastatic tumors (> 1 vs. 1) 0.930 (0.279–3.095) 0.906   
Metastases diameter( > 3 cm vs. ≤ 3 cm) 1.625 (0.795–3.321) 0.183   
Preoperative CEA (> 50 ng/mL vs. ≤ 50 ng/mL) 0.727 (0.334–1.585) 0.423   
Preoperative CA19-9 (> 35 U/mL vs. ≤ 35 U/mL) 0.972 (0.444–2.129) 0.943   
Preoperative chemotherapy (yes vs. no) 1.470 (0.687–3.148) 0.321   
ACT (yes vs. no) 0.402 (0.188–0.858) 0.018 0.350 (0.161–0.759) 0.008
  1. ACT adjuvant chemotherapy, CA19-9 carbohydrate antigen 19-9, CEA carcinoembryonic antigen, CI confidence interval, HR hazard ratio, MSKCC-CRS Memorial Sloan-Kettering Cancer Center clinical risk score